Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03816176 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03816176 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 31 participants.
The verdict
NCT03816176, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
Interventions
- DRUG Isavuconazonium sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03816176
The ClinicalTrials.gov registry entry for NCT03816176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isavuconazonium sulfate is the first listed.
NCT03816176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03816176 about?
NCT03816176 is a clinical study titled "A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants". The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
What is the current status of trial NCT03816176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-08-22. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT03816176?
The interventions under investigation include: Isavuconazonium sulfate (DRUG).
Who is sponsoring clinical trial NCT03816176?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.